Ken Warrington
Sr. Director, Business Development GenScript ProBioKen Warrington, PhD joined GenScript Probio in 2020 as Head of Strategy & Innovation and a Sr. Director of Business Development supporting their Gene & Cell Therapy CMC services. Dr. Warrington served on the faculty at the University of Florida focused on AAV vector development and transitioned into industry where he has served lead technical operation and business development roles for global contract testing and manufacturing organizations. He is a co-founder and director of Lacerta Therapeutics and Chair of the Scientific Advisory Board at Biostem Life Sciences. He has broad expertise across the viral vector product development continuum from discovery through GMP-compliant manufacturing to support IND-enabling preclinical and early stage clinical programs.
January 27, 2021
1:45 PM Implementing a Suspension System in Viral Vector Manufacturing for Cell Therapy
Since two CAR-T products entered into market in 2017, and three gene therapy products marketed from 2017, gene and cell therapy has made great breakthroughs in recent years. The attention to manufacturing of viral vectors is particularly focused on overcoming challenges in developing stable and scalable manufacturing process. Listen to a presentation around robust viral vector manufacturing processes using both adherent culture and suspension culture processes.
In Partnership With :
QUESTIONS?
Contact us: 1-800-882-8684
Email: enquiry@iqpc.com
©2024 IQPC. All rights reserved.
